Aztreonam Side Effects
Medically reviewed by Drugs.com. Last updated on Mar 5, 2024.
Applies to aztreonam: powder for solution. Other dosage forms:
Serious side effects of Aztreonam
Along with its needed effects, aztreonam may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor immediately if any of the following side effects occur while taking aztreonam:
Less common or rare
- Black, tarry stools
- blood in urine or stools
- burning or itching of vagina
- chest pain
- chills
- confusion
- convulsions (seizures)
- cough
- dark urine
- diarrhea
- difficulty in breathing
- discharge from vagina
- discomfort, inflammation, or swelling at the injection site
- dizziness
- eye pain
- fever
- flu-like symptoms
- general feeling of illness
- headache
- hives
- light gray-colored stools
- loss of appetite
- numbness of tongue
- pinpoint red spots on skin
- seeing double
- skin rash, redness, or itching
- sore throat
- unusual bleeding or bruising
- unusual tiredness or weakness
- yellow skin or eyes
Other side effects of Aztreonam
Some side effects of aztreonam may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.
Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:
Less common or rare
- Abdominal or stomach cramps
- altered sense of taste
- bad breath
- breast tenderness
- burning or prickling feeling of skin
- flushing
- increased sweating
- mouth ulcers
- muscular aches
- nasal congestion
- nausea or vomiting
- ringing, buzzing, or noise in ear
- small, nonraised, round, purplish or red spots on skin
- sneezing
- trouble in sleeping
For Healthcare Professionals
Applies to aztreonam: inhalation powder for reconstitution, injectable powder for injection, intravenous solution.
General
Aztreonam for injection was generally well tolerated. The overall incidence of systemic side effects was about 1% to 1.3%.[Ref]
Respiratory
Aztreonam for inhalation:
Very common (10% or more): Cough (54%), nasal congestion (16%), wheezing (16%)
Common (1% to 10%): Bronchospasm (3%)
Postmarketing reports: Dyspnea
Aztreonam for injection:
Uncommon (0.1% to 1%): Less than 1%: Wheezing, dyspnea, chest pain, sneezing, nasal congestion[Ref]
Other
Aztreonam for inhalation:
Very common (10% or more): Pyrexia (13%), pharyngolaryngeal pain (12%)
Common (1% to 10%): Chest discomfort (8%), abdominal pain (7%)
Aztreonam for injection:
Common (1% to 10%): Superinfection (up to 10%)
Uncommon (0.1% to 1%): Less than 1%: Weakness, fever, malaise, flushing[Ref]
Superinfection has been reported in up to 10% of patients during aztreonam therapy and was usually due to enterococcus or staphylococcus.[Ref]
Gastrointestinal
Aztreonam for inhalation:
Common (1% to 10%): Vomiting (6%)
Aztreonam for injection:
Common (1% to 10%): 1% to 1.3%: Nausea, vomiting, diarrhea
Uncommon (0.1% to 1%): Less than 1%: Abdominal cramps, mouth ulcer, altered taste, numb tongue, halitosis
Rare (less than 0.1%): Clostridium difficile associated diarrhea, pseudomembranous colitis, gastrointestinal bleeding[Ref]
Onset of pseudomembranous colitis symptoms may occur during or after antibiotic treatment.[Ref]
Dermatologic
Aztreonam for inhalation:
Common (1% to 10%): Rash (2%)
Aztreonam for injection:
Common (1% to 10%): Rash (1% to 1.3%)
Uncommon (0.1% to 1%): Less than 1%: Toxic epidermal necrolysis, purpura, erythema multiforme, exfoliative dermatitis, urticaria, petechiae, pruritus, diaphoresis[Ref]
Toxic epidermal necrolysis associated with aztreonam has been reported in very ill patients on many other medications, making implication of aztreonam difficult.[Ref]
Local
Aztreonam for injection:
Common (1% to 10%): Discomfort/swelling at the injection site after intramuscular administration (2.4%), phlebitis/thrombophlebitis after intravenous administration (1.9%)[Ref]
Hypersensitivity
Aztreonam for inhalation:
Frequency not reported: Allergic reaction (with facial rash, facial swelling, throat tightness)
Aztreonam for injection:
Uncommon (0.1% to 1%): Less than 1%: Anaphylaxis, angioedema, bronchospasm
Rare (less than 0.1%): Maculopapular eruption (at least 1 case)[Ref]
A 57-year-old male developed a widespread maculopapular eruption two hours after receiving aztreonam. Corticosteroids and antihistamines were needed to control the reaction which disappeared after 8 days. The patient also showed cross-reactivity to ceftazidime which shares the same side chain as aztreonam.[Ref]
Hematologic
Aztreonam for injection:
Uncommon (0.1% to 1%): Less than 1%: Pancytopenia, neutropenia, thrombocytopenia, anemia, eosinophilia, leukocytosis, thrombocytosis
Frequency not reported: Increased prothrombin time, increased partial thromboplastin time, positive Coombs' test[Ref]
A case of myelosuppression associated with aztreonam has been reported, but because many other drugs were administered and because the patient was bacteremic, implication of aztreonam as the causative agent was difficult.
In vitro studies have shown that aztreonam may inhibit ADP-induced platelet aggregation at high concentrations. Clinically, therapeutic doses of aztreonam have not been associated with bleeding problems.[Ref]
Hepatic
Aztreonam for injection:
Uncommon (0.1% to 1%): Less than 1%: Hepatitis, jaundice, signs or symptoms of hepatobiliary dysfunction
Frequency not reported: Elevated AST, elevated ALT, elevated alkaline phosphatase[Ref]
Cardiovascular
Aztreonam for injection:
Uncommon (0.1% to 1%): Hypotension (less than 1%), transient electrocardiogram changes (ventricular bigeminy, premature ventricular contractions; less than 1%)[Ref]
Nervous system
Aztreonam for injection:
Uncommon (0.1% to 1%): Less than 1%: Seizure, headache, confusion, vertigo, paresthesia, insomnia, dizziness, tinnitus[Ref]
Musculoskeletal
Aztreonam for inhalation:
Postmarketing reports: Arthralgia, joint swelling
Aztreonam for injection:
Uncommon (0.1% to 1%): Muscular aches (less than 1%)[Ref]
Renal
Aztreonam for injection:
Rare (less than 0.1%): Acute interstitial nephritis (at least 1 case)
Frequency not reported: Increased serum creatinine[Ref]
Acute interstitial nephritis associated with aztreonam has been reported in a very ill patient receiving many other medications.[Ref]
Genitourinary
Aztreonam for injection:
Uncommon (0.1% to 1%): Less than 1%: Vaginal candidiasis, vaginitis, breast tenderness[Ref]
Ocular
Aztreonam for injection:
Uncommon (0.1% to 1%): Diplopia (less than 1%)[Ref]
More about aztreonam
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (1)
- Dosage information
- During pregnancy
- Drug class: miscellaneous antibiotics
- Breastfeeding
Patient resources
- Aztreonam inhalation drug information
- Aztreonam injection
- Aztreonam (Inhalation) (Advanced Reading)
- Aztreonam (Intravenous, Injection) (Advanced Reading)
- Aztreonam (Oral Inhalation)
- Aztreonam (Systemic)
Other brands
Professional resources
Other brands
Related treatment guides
References
1. Product Information. Azactam (aztreonam). Bristol-Myers Squibb. 2002;PROD.
2. Aztreonam for inhalation solution (cayston) for cystic fibrosis. Med Lett Drugs Ther. 2010;52:63-4.
3. Newman TJ, Dreslinski GR, Tadros SS. Safety profile of aztreonam in clinical trials. Rev Infect Dis. 1985;7:s648-55.
4. Daikos GK. Clinical experience with aztreonam in four Mediterranean countries. Rev Infect Dis. 1985;7:s831-5.
5. Norrby SR. Clinical experience with aztreonam in Europe: a summary of studies in Belgium, England, Finland, Ireland, the Netherlands, Norway, Portugal, and Sweden. Rev Infect Dis. 1985;7:s836-9.
6. Brogden RN, Heel RC. Aztreonam: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs. 1986;31:96-130.
7. Aztreonam (azactam). Med Lett Drugs Ther. 1987;29:45-6.
8. Chartrand SA. Safety and toxicity profile of aztreonam. Pediatr Infect Dis J. 1989;8:s120-3,128-32.
9. Ramakrishnan K, Scheid DC. Diagnosis and management of acute pyelonephritis in adults. Am Fam Physician. 2005;71:933-42.
10. Guay DR, Koskoletos C. Aztreonam, a new monobactam antimicrobial. Clin Pharm. 1985;4:516-26.
11. Hopefl AW. Aztreonam: an overview. Drug Intell Clin Pharm. 1985;19:165-9.
12. Hara K, Kobayashi H, Nishiura T, Yura J, Saito A. Clinical studies of aztreonam in Japan. Rev Infect Dis. 1985;7:s810-24.
13. Pasmino P. Acute renal failure, skin rash, and eosinophilia associated with aztreonam. Am J Nephrol. 1988;8:68-70.
14. Alvarez JS, del Castillo JA, Garcia IS, Ortiz MJ. Immediate hypersensitivity to aztreonam. Lancet. 1990;335:1094.
15. Clergeot A, Steru D, Rosset MA, Carbon C. Efficacy and safety of low-dose aztreonam in the treatment of moderate to severe infections due to gram-negative bacilli. Rev Infect Dis. 1991;13:s648-51.
16. Sion ML, Pyrpasopoulos M, Nicolaidis P, Papagianni C, Tsurutsoglu G. Efficacy and safety of aztreonam in the treatment of patients with renal failure. Rev Infect Dis. 1991;13:s652-4.
17. Hantson P, de Coninck B, Horn JL, Mahieu P. Immediate hypersensitivity to aztreonam and imipenem. Br Med J. 1991;302:294-5.
18. McDonald BJ, Singer JW, Bianco JA. Toxic epidermal necrolysis possibly linked to aztreonam in bone marrow transplant patients. Ann Pharmacother. 1992;26:34-5.
19. Prieto RD, Medina AA, Palla PS, Perez JMD, Merino MES, Garcia AF. Urticaria caused by sensitization to aztreonam. Allergy. 1993;48:634-6.
20. Pimiento AP, Martinez MG, Mena AM, Gonzalez AT, Arranz SD, Mosquera MR. Aztreonam and ceftazidime: evidence of in vivo cross-allergenicity. Allergy. 1998;53:624-5.
21. Stille W, Gillissen J. Clinical experience with aztreonam in Germany and Austria. Rev Infect Dis. 1985;7:s825-30.
22. Dallal MM, Czachor JS. Aztreonam-induced myelosuppression during treatment of pseudomonas aeruginosa pneumonia. DICP. 1991;25:594-7.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Some side effects may not be reported. You may report them to the FDA.